Sundia congratulates Betta Pharmaceuticals for X-396 IND approval in China
Shanghai, August 31, 2016 – Betta Pharmaceuticals Co., Ltd. has successfully received X-396 CFDA IND approval in the class 1.1 IND application. The innovative target therapy, X-396, is aim to provide treatments f
August 31, 2016